MarkWide Research

Sale!

Cancer Diagnostics Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: October, 2022
No of Pages: 159
Delivery Format: PDF+Excel

$2,950.00

Cancer Diagnostics Market size exceeded USD 116.5 billion in 2020 and is anticipated to grow at a CAGR of over 8.6% between 2021 and 2027. Increasing adoption of sedentary lifestyle involving relatively lesser amount of physical exercise has escalated the incidence of cancer cases globally.

COVID-19 pandemic has negatively impacted the cancer care programs or cancer market in many countries. Moreover, the R&D programs involving product development and clinical trials focusing on cancer diagnostics were also hampered with the onset of COVID-19 pandemic. As medical device manufacturers and other stakeholders in the supply chain laid significant emphasis on the development and production of COVID-19 related goods and ancillaries.

Favorable government initiatives to create cancer awareness to spur the market growth

Numerous efforts are undertaken by private organizations and public authorities to create awareness surrounding cancer. For instance, in 2019, the Government of India launched a cancer campaign to remove the stigma surrounding cancer.

High cost associated diagnostic imaging system may slow down the market expansion

The increasing demand for cancer diagnostic tests coupled with technological advancements with faster results and accuracy has escalated the price associated with imaging cancer diagnostics. The usage of imaging diagnostics has grown exponentially over the last decade in the industry. However, in several countries it is observed that several cancer diagnostic services are not fully covered by insurance.

Imaging technique plays a crucial role in cancer diagnosis

The imaging segment dominated more than 65% of the cancer diagnostics market share in 2020. Detecting cancer with an imaging test helps the healthcare professionals in deciding the course of treatment for the patient. With the increasing cancer prevalence, demand for imaging modalities is rapidly growing in the global market.
To meet the growing demand, new technologies and techniques are commercialized by market players, intensifying the existing competition. Furthermore, technological advancements largely contribute to the industry growth by boosting its acceptance rates.

Increasing incidence of breast cancer globally

Breast cancer segment was valued at USD 21.7 billion in 2020. The upsurge in breast cancer cases are increasingly due to gene mutation. It is estimated that nearly 5% to 10% of breast cancer cases reported globally are inherited. Additionally, unhealthy lifestyle, obesity and reduced childbearing can be directly linked with breast cancer incidence, as it increases estrogen levels in the female body.

Rising number of hospital admissions for cancer diagnosis and treatment will enhance the segment growth

The hospital segment captured 41% of revenue share in 2020. Hospitals represent a high adoption rate for expensive and advanced imaging modalities alongside other diagnostic devices.

Relatively better acceptance trends and presence of key companies will fuel the growth of North America region

North America cancer diagnostics market accounted for 42% of revenue share in 2020. Technological advancements in diagnostic tests, increasing healthcare expenditure and higher patient awareness regarding early cancer diagnosis are some of the prime factors contributing to increasing diagnostics uptake in the region.
Moreover, rising tobacco and alcohol consumption as well as suboptimal lifestyle standards lead to the incidence of various types of cancer. Furthermore, the strong foothold of key companies in the region coupled with favorable R&D initiatives will favor the industry expansion.

Organic growth strategies pave growth opportunities for leaders operating in the market

Prominent players operating in the market include Abbott, Becton, Dickinson and Company, Biocartis, Siemens Healthineers, GE Healthcare, Janssen Diagnostic LLC and Sysmex Corporation. Product launch & approval, geographical expansion, partnership, and collaborations are the most commonly adopted business strategies to sustain market competition and position.

The market research report of cancer diagnostics includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Product

  • Tumor biomarkers tests
  • Imaging
    • Ultrasound and radiology
    • Mammography
    • MRI scan
    • PET scan
    • CT scan
    • SPECT & others
  • Biopsy
  • Liquid biopsy
  • Immunohistochemistry
  • In situ hybridization

Market, By Cancer type

  • Bladder cancer
  • Breast cancer
  • Colon and rectal cancer
  • Endometrial cancer
  • Kidney cancer
  • Leukemia
  • Liver-lung cancer
  • Melanoma
  • Non-Hodgkin lymphoma
  • Pancreatic cancer
  • Prostate cancer
  • Thyroid cancer
  • Others

By End-use

  • Hospitals
  • Diagnostic laboratories
  • Diagnostic imaging centers
  • Cancer research institutes

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Chapter 1   Methodology

1.1    Market definitions

1.2    Base estimates & working

1.2.1    North America

1.2.2    Europe

1.2.3    Asia Pacific

1.2.4    Latin America

1.2.5    Middle East & Africa

1.3    Forecast parameters

1.4    Data validation

1.5    Data Sources

1.5.1    Secondary

1.5.1.1    Paid sources

1.5.1.2    Unpaid sources

1.5.2    Primary

Chapter 2   Executive Summary

2.1    Cancer diagnostics industry 360° synopsis, 2016-2027

2.1.1    Business trends

2.1.2    Application trends

2.1.3    Cancer type trends

2.1.4    End-use trends

2.1.5    Regional trends

Chapter 3   Cancer Diagnostics Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2016 – 2027

3.3    Industry impact forces

3.3.1    Growth drivers

3.3.1.1    Rising incidence of cancer globally

3.3.1.2    Several initiatives undertaken by government and other organizations to spread disease awareness

3.3.1.3    Growing number of diagnostic laboratories in developed countries

3.3.1.4    Technological advancements in developed countries

3.3.2    Industry pitfalls & challenges

3.3.2.1    High capital investment coupled with high cost associated with diagnostic imaging system

3.3.2.2    Risk related with high radiation exposure affecting use of CT scanner

3.4    Growth potential analysis

3.4.1    By application

3.4.2    By cancer type

3.4.3    By end-use

3.5    COVID-19 impact analysis

3.6    Porter’s analysis

3.7    Competitive landscape

3.7.1    Company matrix analysis, 2020

3.8    PESTEL analysis

Chapter 4   Cancer Diagnostics Market, By Application

4.1    Key segment trends

4.2    Tumor biomarkers tests

4.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.3    Imaging

4.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.2    Ultrasound and radiology

4.3.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.3    Mammography

4.3.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.4    MRI scan

4.3.4.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.5    PET scan

4.3.5.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.6    CT scan

4.3.6.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.7    SPECT & others

4.3.7.1    Market size, by region, 2016 – 2027 (USD Million)

4.4    Biopsy

4.4.1    Market size, by region, 2016 – 2027 (USD Million)

4.5    Liquid biopsy

4.5.1    Market size, by region, 2016 – 2027 (USD Million)

4.6    Immunohistochemistry

4.6.1    Market size, by region, 2016 – 2027 (USD Million)

4.7    In situ hybridization

4.7.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 5   Cancer Diagnostics Market, By Cancer type

5.1    Key segment trends

5.2    Bladder cancer

5.2.1    Market size, by region, 2016 – 2027 (USD Million)

5.3    Breast cancer

5.3.1    Market size, by region, 2016 – 2027 (USD Million)

5.4    Colon and rectal cancer

5.4.1    Market size, by region, 2016 – 2027 (USD Million)

5.5    Endometrial cancer

5.5.1    Market size, by region, 2016 – 2027 (USD Million)

5.6    Kidney cancer

5.6.1    Market size, by region, 2016 – 2027 (USD Million)

5.7    Leukemia

5.7.1    Market size, by region, 2016 – 2027 (USD Million)

5.8    Liver-lung cancer

5.8.1    Market size, by region, 2016 – 2027 (USD Million)

5.9    Melanoma

5.9.1    Market size, by region, 2016 – 2027 (USD Million)

5.10    Non-Hodgkin lymphoma

5.10.1    Market size, by region, 2016 – 2027 (USD Million)

5.11    Pancreatic cancer

5.11.1    Market size, by region, 2016 – 2027 (USD Million)

5.12    Prostate cancer

5.12.1    Market size, by region, 2016 – 2027 (USD Million)

5.13    Thyroid cancer

5.13.1    Market size, by region, 2016 – 2027 (USD Million)

5.14    Others

5.14.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 6   Cancer Diagnostics Market, By End-use

6.1    Key segment trends

6.2    Hospitals

6.2.1    Market size, by region, 2016 – 2027 (USD Million)

6.3    Diagnostic laboratories

6.3.1    Market size, by region, 2016 – 2027 (USD Million)

6.4    Diagnostic imaging centers

6.4.1    Market size, by region, 2016 – 2027 (USD Million)

6.5    Cancer research institutes

6.5.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 7   Cancer Diagnostics Market, By Region

7.1    Key regional trends

7.2    North America

7.2.1    Market size, by country, 2016 – 2027 (USD Million)

7.2.2    Market size, by application, 2016 – 2027 (USD Million)

7.2.2.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.2.3    Market size, by cancer type, 2016 – 2027 (USD Million)

7.2.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.2.5    U.S.

7.2.5.1    Market size, by application, 2016 – 2027 (USD Million)

7.2.5.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.2.5.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.2.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.2.6    Canada

7.2.6.1    Market size, by application, 2016 – 2027 (USD Million)

7.2.6.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.2.6.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.2.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3    Europe

7.3.1    Market size, by country, 2016 – 2027 (USD Million)

7.3.2    Market size, by application, 2016 – 2027 (USD Million)

7.3.2.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.3.3    Market size, by cancer type, 2016 – 2027 (USD Million)

7.3.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.5    Germany

7.3.5.1    Market size, by application, 2016 – 2027 (USD Million)

7.3.5.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.3.5.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.3.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.6    UK

7.3.6.1    Market size, by application, 2016 – 2027 (USD Million)

7.3.6.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.3.6.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.3.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.7    France

7.3.7.1    Market size, by application, 2016 – 2027 (USD Million)

7.3.7.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.3.7.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.3.7.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.8    Italy

7.3.8.1    Market size, by application, 2016 – 2027 (USD Million)

7.3.8.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.3.8.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.3.8.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.9    Spain

7.3.9.1    Market size, by application, 2016 – 2027 (USD Million)

7.3.9.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.3.9.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.3.9.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.10    Russia

7.3.10.1    Market size, by application, 2016 – 2027 (USD Million)

7.3.10.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.3.10.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.3.10.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.4    Asia Pacific

7.4.1    Market size, by country, 2016 – 2027 (USD Million)

7.4.2    Market size, by application, 2016 – 2027 (USD Million)

7.4.2.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.4.3    Market size, by cancer type, 2016 – 2027 (USD Million)

7.4.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.4.5    Japan

7.4.5.1    Market size, by application, 2016 – 2027 (USD Million)

7.4.5.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.4.5.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.4.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.4.6    China

7.4.6.1    Market size, by application, 2016 – 2027 (USD Million)

7.4.6.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.4.6.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.4.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.4.7    India

7.4.7.1    Market size, by application, 2016 – 2027 (USD Million)

7.4.7.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.4.7.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.4.7.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.4.8    Australia

7.4.8.1    Market size, by application, 2016 – 2027 (USD Million)

7.4.8.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.4.8.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.4.8.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.5    Latin America

7.5.1    Market size, by country, 2016 – 2027 (USD Million)

7.5.2    Market size, by application, 2016 – 2027 (USD Million)

7.5.2.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.5.3    Market size, by cancer type, 2016 – 2027 (USD Million)

7.5.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.5.5    Brazil

7.5.5.1    Market size, by application, 2016 – 2027 (USD Million)

7.5.5.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.5.5.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.5.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.5.6    Mexico

7.5.6.1    Market size, by application, 2016 – 2027 (USD Million)

7.5.6.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.5.6.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.5.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.5.7    Argentina

7.5.7.1    Market size, by application, 2016 – 2027 (USD Million)

7.5.7.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.5.7.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.5.7.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.6    MEA

7.6.1    Market size, by country, 2016 – 2027 (USD Million)

7.6.2    Market size, by application, 2016 – 2027 (USD Million)

7.6.2.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.6.3    Market size, by cancer type, 2016 – 2027 (USD Million)

7.6.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.6.5    South Africa

7.6.5.1    Market size, by application, 2016 – 2027 (USD Million)

7.6.5.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.6.5.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.6.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.6.6    Saudi Arabia

7.6.6.1    Market size, by application, 2016 – 2027 (USD Million)

7.6.6.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.6.6.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.6.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.6.7    UAE

7.6.7.1    Market size, by application, 2016 – 2027 (USD Million)

7.6.7.1.1    Market size, by imaging, 2016 – 2027 (USD Million)

7.6.7.2    Market size, by cancer type, 2016 – 2027 (USD Million)

7.6.7.3    Market size, by end-use, 2016 – 2027 (USD Million)

Chapter 8   Company Profiles

8.1    Competitive dashboard, 2020

8.2    Abbott Laboratories

8.2.1    Business overview

8.2.2    Financial data

8.2.3    Product landscape

8.2.4    Strategic outlook

8.2.5    SWOT analysis

8.3    AB Sciex Pte. Ltd

8.3.1    Business overview

8.3.2    Financial data

8.3.3    Product landscape

8.3.4    Strategic outlook

8.3.5    SWOT analysis

8.4    Agilent Technologies Inc

8.4.1    Business overview

8.4.2    Financial data

8.4.3    Product landscape

8.4.4    Strategic outlook

8.4.5    SWOT analysis

8.5    Becton, Dickinson and Company

8.5.1    Business overview

8.5.2    Financial data

8.5.3    Product landscape

8.5.4    Strategic outlook

8.5.5    SWOT analysis

8.6    Biocare Medical LLC

8.6.1    Business overview

8.6.2    Financial data

8.6.3    Product landscape

8.6.4    Strategic outlook

8.6.5    SWOT analysis

8.7    Biocartis

8.7.1    Business overview

8.7.2    Financial data

8.7.3    Product landscape

8.7.4    Strategic outlook

8.7.5    SWOT analysis

8.8    BioMerieux SA

8.8.1    Business overview

8.8.2    Financial data

8.8.3    Product landscape

8.8.4    Strategic outlook

8.8.5    SWOT analysis

8.9    Bio-Rad Laboratories

8.9.1    Business overview

8.9.2    Financial data

8.9.3    Product landscape

8.9.4    Strategic outlook

8.9.5    SWOT analysis

8.10    Cancer Genetics Inc

8.10.1    Business overview

8.10.2    Financial data

8.10.3    Product landscape

8.10.4    Strategic outlook

8.10.5    SWOT analysis

8.11    GE Healthcare

8.11.1    Business overview

8.11.2    Financial data

8.11.3    Product landscape

8.11.4    Strategic outlook

8.11.5    SWOT analysis

8.12    Hologic Inc

8.12.1    Business overview

8.12.2    Financial data

8.12.3    Product landscape

8.12.4    Strategic outlook

8.12.5    SWOT analysis

8.13    Janssen Diagnostics LLC (Johnson & Johnson)

8.13.1    Business overview

8.13.2    Financial data

8.13.3    Product landscape

8.13.4    Strategic outlook

8.13.5    SWOT analysis

8.14    Leica Biosystem Nussloch GmbH (Danaher Corporation)

8.14.1    Business overview

8.14.2    Financial data

8.14.3    Product landscape

8.14.4    Strategic outlook

8.14.5    SWOT analysis

8.15    Myriad Genetics, Inc

8.15.1    Business overview

8.15.2    Financial data

8.15.3    Product landscape

8.15.4    Strategic outlook

8.15.5    SWOT analysis

8.16    Qiagen N.V

8.16.1    Business overview

8.16.2    Financial data

8.16.3    Product landscape

8.16.4    Strategic outlook

8.16.5    SWOT analysis

8.17    F-Hoffmann-La Roche Ltd

8.17.1    Business overview

8.17.2    Financial data

8.17.3    Product landscape

8.17.4    Strategic outlook

8.17.5    SWOT analysis

8.18    Siemens Healthineers

8.18.1    Business overview

8.18.2    Financial data

8.18.3    Product landscape

8.18.4    Strategic outlook

8.18.5    SWOT analysis

8.19    Sysmex Corporation

8.19.1    Business overview

8.19.2    Financial data

8.19.3    Product landscape

8.19.4    Strategic outlook

8.19.5    SWOT analysis

8.20    Thermo Fischer Scientific

8.20.1    Business overview

8.20.2    Financial data

8.20.3    Product landscape

8.20.4    Strategic outlook

8.20.5    SWOT analysis

Data Tables

TABLE 1    Cancer diagnostics industry 3600 synopsis, 2016 – 2027

TABLE 2    Global cancer diagnostics market, 2016 – 2020 (USD Million)

TABLE 3    Global cancer diagnostics market, 2021 – 2027 (USD Million)

TABLE 4    Global cancer diagnostics market, by application, 2016 – 2020 (USD Million)

TABLE 5    Global cancer diagnostics market, by application, 2021 – 2027 (USD Million)

TABLE 6    Global cancer diagnostics market, by cancer type, 2016 – 2020 (USD Million)

TABLE 7    Global cancer diagnostics market, by cancer type, 2021 – 2027 (USD Million)

TABLE 8    Global cancer diagnostics market, by end-use, 2016 – 2020 (USD Million)

TABLE 9    Global cancer diagnostics market, by end-use, 2021 – 2027 (USD Million)

TABLE 10    Global cancer diagnostics market, by region, 2016 – 2020 (USD Million)

TABLE 11    Global cancer diagnostics market, by region, 2021 – 2027 (USD Million)

TABLE 12    Industry impact forces

TABLE 13    Tumor biomarkers tests market size, by region, 2016 – 2020 (USD Million)

TABLE 14    Tumor biomarkers tests market size, by region, 2021 – 2027 (USD Million)

TABLE 15    Imaging market size, by region, 2016 – 2020 (USD Million)

TABLE 16    Imaging market size, by region, 2021 – 2027 (USD Million)

TABLE 17    Ultrasound and radiology market size, by region, 2016 – 2020 (USD Million)

TABLE 18    Ultrasound and radiology market size, by region, 2021 – 2027 (USD Million)

TABLE 19    Mammography market size, by region, 2016 – 2020 (USD Million)

TABLE 20    Mammography market size, by region, 2021 – 2027 (USD Million)

TABLE 21    MRI Scan market size, by region, 2016 – 2020 (USD Million)

TABLE 22    MRI Scan market size, by region, 2021 – 2027 (USD Million)

TABLE 23    PET Scan market size, by region, 2016 – 2020 (USD Million)

TABLE 24    PET Scan market size, by region, 2021 – 2027 (USD Million)

TABLE 25    CT Scan market size, by region, 2016 – 2020 (USD Million)

TABLE 26    CT Scan market size, by region, 2021 – 2027 (USD Million)

TABLE 27    SPECT and others market size, by region, 2016 – 2020 (USD Million)

TABLE 28    SPECT and others market size, by region, 2021 – 2027 (USD Million)

TABLE 29    Biopsy market size, by region, 2016 – 2020 (USD Million)

TABLE 30    Biopsy market size, by region, 2021 – 2027 (USD Million)

TABLE 31    Liquid biopsy market size, by region, 2016 – 2020 (USD Million)

TABLE 32    Liquid biopsy market size, by region, 2021 – 2027 (USD Million)

TABLE 33    Immunohistochemistry market size, by region, 2016 – 2020 (USD Million)

TABLE 34    Immunohistochemistry market size, by region, 2021 – 2027 (USD Million)

TABLE 35    In situ hybridization market size, by region, 2016 – 2020 (USD Million)

TABLE 36    In situ hybridization market size, by region, 2021 – 2027 (USD Million)

TABLE 37    Bladder cancer market size, by region, 2016 – 2020 (USD Million)

TABLE 38    Bladder cancer market size, by region, 2021 – 2027 (USD Million)

TABLE 39    Breast cancer market size, by region, 2016 – 2020 (USD Million)

TABLE 40    Breast cancer market size, by region, 2021 – 2027 (USD Million)

TABLE 41    Colon and rectal cancer market size, by region, 2016 – 2020 (USD Million)

TABLE 42    Colon and rectal cancer market size, by region, 2021 – 2027 (USD Million)

TABLE 43    Endometrial cancer market size, by region, 2016 – 2020 (USD Million)

TABLE 44    Endometrial cancer market size, by region, 2021 – 2027 (USD Million)

TABLE 45    Kidney cancer market size, by region, 2016 – 2020 (USD Million)

TABLE 46    Kidney cancer market size, by region, 2021 – 2027 (USD Million)

TABLE 47    Leukemia market size, by region, 2016 – 2020 (USD Million)

TABLE 48    Leukemia market size, by region, 2021 – 2027 (USD Million)

TABLE 49    Liver-lung cancer market size, by region, 2016 – 2020 (USD Million)

TABLE 50    Liver-lung cancer market size, by region, 2021 – 2027 (USD Million)

TABLE 51    Melanoma market size, by region, 2016 – 2020 (USD Million)

TABLE 52    Melanoma market size, by region, 2021 – 2027 (USD Million)

TABLE 53    Non-Hodgkin lymphoma market size, by region, 2016 – 2020 (USD Million)

TABLE 54    Non-Hodgkin lymphoma market size, by region, 2021 – 2027 (USD Million)

TABLE 55    Pancreatic cancer market size, by region, 2016 – 2020 (USD Million)

TABLE 56    Pancreatic cancer market size, by region, 2021 – 2027 (USD Million)

TABLE 57    Prostate cancer market size, by region, 2016 – 2020 (USD Million)

TABLE 58    Prostate cancer market size, by region, 2021 – 2027 (USD Million)

TABLE 59    Thyroid cancer market size, by region, 2016 – 2020 (USD Million)

TABLE 60    Thyroid cancer market size, by region, 2021 – 2027 (USD Million)

TABLE 61    Others market size, by region, 2016 – 2020 (USD Million)

TABLE 62    Others market size, by region, 2021 – 2027 (USD Million)

TABLE 63    Hospitals market size, by region, 2016 – 2020 (USD Million)

TABLE 64    Hospitals market size, by region, 2021 – 2027 (USD Million)

TABLE 65    Diagnostic laboratories market size, by region, 2016 – 2020 (USD Million)

TABLE 66    Diagnostic laboratories market size, by region, 2021 – 2027 (USD Million)

TABLE 67    Diagnostic imaging centers market size, by region, 2016 – 2020 (USD Million)

TABLE 68    Diagnostic imaging centers market size, by region, 2021 – 20

Market, By Product

  • Tumor biomarkers tests
  • Imaging
    • Ultrasound and radiology
    • Mammography
    • MRI scan
    • PET scan
    • CT scan
    • SPECT & others
  • Biopsy
  • Liquid biopsy
  • Immunohistochemistry
  • In situ hybridization

Market, By Cancer type

  • Bladder cancer
  • Breast cancer
  • Colon and rectal cancer
  • Endometrial cancer
  • Kidney cancer
  • Leukemia
  • Liver-lung cancer
  • Melanoma
  • Non-Hodgkin lymphoma
  • Pancreatic cancer
  • Prostate cancer
  • Thyroid cancer
  • Others

By End-use

  • Hospitals
  • Diagnostic laboratories
  • Diagnostic imaging centers
  • Cancer research institutes

Abbott, Becton, Dickinson and Company, Biocartis, Siemens Healthineers, GE Healthcare, Janssen Diagnostic LLC and Sysmex Corporation.

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF